跳至主要内容
临床试验/EUCTR2017-001555-32-DE
EUCTR2017-001555-32-DE进行中(未招募)1 期

A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER). - AMBER

ovartis Pharma AG0 个研究点目标入组 65 人开始时间: 2017年10月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
65

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - AIH diagnosed per International Autoimmune Hepatitis Group
  • - Liver biopsy with Ishak modified HAI indicating active AIH
  • - Incomplete response to OR intolerance of standard therapy (per AASLD)
  • Other protocol-defined inclusion criteria may apply
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 55
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • - Prior use of any B-cell depleting therapy
  • - Required regular use of medications with known hepatotoxicity
  • - Decompensated cirrhosis
  • - Diagnosis of overlap syndrome with AIH (e.g., AIH+PBC, AIH+PSC)
  • - Drug related AIH at screening or a history of drug related AIH
  • - History of drug abuse or unhealthy alcohol use
  • - History of malignancy of any organ system
  • - Pregnant or nursing (lactating) women
  • - Other protocol-defined exclusion criteria may apply

研究者

相似试验